GZD 824

GZD 824 Basic information

Product Name:	GZD 824
Synonyms:	GZD-824; GZD 824;BENZAMIDE;4-Methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide;3-(2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;GZD8824;GZD824;GZD-824;GZD 824;GZD-824 Free;GZD 824;GZD824
CAS:	1257628-77-5
MF:	C29H27F3N6O
MW:	532.56
EINECS:
Product Categories:	Inhibitors
Mol File:	1257628-77-5.mol

GZD 824 Chemical Properties

Boiling point	630.4±55.0 °C(Predicted)
density	1.39±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMSO : ≥ 100 mg/mL (187.77 mM)
form	A crystalline solid
pka	9.04±0.40(Predicted)

Safety Information

MSDS Information

GZD 824 Usage And Synthesis

Description

GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC₅₀s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/Abl^T315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC₅₀s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl.

Uses

GZD824 is a orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) kinases. It is a COVID19-related research product.

GZD 824 Preparation Products And Raw materials

Raw materials

1H-Pyrazolo[3,4-b]pyridine, 5-[2-(trimethylsilyl)ethynyl]--->4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline-->5-BROMO-1H-PYRAZO[3,4-B]PYRIDINE-->4-b]pyridine-->METHYL 3-IODO-4-METHYLBENZOATE

Tofacitinib Lenvatinib NS-398 Dacomitinib (PF299804) ACTIN FROM RABBIT MUSCLE Trametinib Palbociclib Cabozantinib Axitinib Nilotinib hydrochloride anhydrous

Email:[email protected] [email protected]

GZD 824

Login

Fast registration